Daxor Corporation Announces Second Quarter 2006 Earnings.NEW YORK New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of -- Daxor Corporation, (AMEX AMEX See: American Stock Exchange : DXR DXR Danbury Municipal Airport, Danbury CT (airport code) DXR Data Extraction and Recording DXR X-Director DXR Dynamic Extended Resolution ):
Three Months Ended Six Months Ended
June 30 June 30
------------------------- -------------------------
2006 2005 2006 2005
------------ ------------ ------------ ------------
Total Operating
Revenues $ 389,322 $ 287,690 $ 731,468 $ 588,046
Total Costs &
Expenses $ 1,914,928 $ 1,484,751 $ 3,529,193 $ 3,023,164
Total Other
Income(Loss) $ 1,659,926 $ (68,006) $ 2,893,063 $ 699,924
Net Income (Loss) $ 134,320 $(1,265,067) $ 95,338 $(1,735,194)
Weighted Average
Number
of Shares
Outstanding 4,629,626 4,644,126 4,630,026 4,639,293
Earnings (Loss)
Per Share $ 0.03 $ (0.27) $ 0.02 $ (0.37)
Daxor Corporation, (AMEX: DXR), a medical instrumentation and biotechnology company, today announced second quarter earnings for 2006. For the six months ended June 30, 2006 total operating revenues increased by 24.4 % to $731,468 from $588,046 in 2005. For the six months ended June 30, 2006 cost and expenses increased by 16.7% to $ 3,529,193 from $ 3,023,164 in 2005. At June 30, 2006 the Company had total assets of $61,307,973 with stockholders' equity Stockholders' Equity The portion of the balance sheet that includes capital received from investors in exchange for stock (paid-in capital), donated capital, and retained earnings. This is equal to total assets minus liabilities, preferred stock and intangible assets. of $ 40,702,331 vs. total assets of $59,565,053 and $38,744,801 of stockholders' equity for December 31, 2005. In the first half of 2006 the company had significant income from investments which helped offset operating losses. The company is increasing its research and development and will be filing 1 - 2 patents in the 2nd half of 2006. One patent will be in the blood banking field. The Company continue to expand its sales and marketing force, which currently consists of 20 salesmen and 4 support personnel. Currently, there are instruments that have been placed for trial that can convert into sales over the upcoming quarters. Among nationally renowned hospitals and other major medical institutions which have purchased the BVA-100 Blood Volume Analyzer after a trial period are the Mayo Clinic Mayo Clinic: see Mayo, Charles Horace. Mayo Clinic voluntary association of more than 500 physicians in Rochester, Minnesota. [Am. Hist.: EB, 11: 723] See : Medicine , The Cleveland Clinic Cleveland Clinic (formally known as the Cleveland Clinic Foundation) is a multispecialty academic medical center located in Cleveland, Ohio, USA. Cleveland Clinic was established in 1921 by four physicians for the purpose of providing patient care, research, and medical , NIH "Not invented here." See digispeak. NIH - The United States National Institutes of Health. , and New York University New York University, mainly in New York City; coeducational; chartered 1831, opened 1832 as the Univ. of the City of New York, renamed 1896. It comprises 13 schools and colleges, maintaining 4 main centers (including the Medical Center) in the city, as well as the Medical Center. During the trial period, the Company receives income primarily from kit sales. Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with a single use diagnostic kit. The BVA-100 measures blood volume to within a 98% accuracy. More information about the BVA-100 and other Daxor products and services can be found at www.daxor.com. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion